StockNews.AI
MRNA
StockNews.AI
186 days

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

1. Moderna reports $1.1 billion net loss and $3.2 billion annual revenue. 2. Expecting $1.5 to $2.5 billion revenue in 2025 with multiple products pending approval.

Earnings
+3.35%Current Return
VS
0%S&P 500
$31.9202/14 06:33 AM EDTEvent Start
$32.9902/17 06:42 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Neutral?

The revenue forecast improvement may not significantly affect MRNA's current stock, similar to past fluctuations post-earnings that showed a calm investor response.

How important is it?

Quarterly performance and future guidance are critical but reflected expectations, with potential volatility around approval news.

Why Short Term?

The quarterly results impact immediate investor sentiment but may stabilize quickly, resembling previous earnings periods for biotech firms.

Related Companies

BNTXNVAXPFE
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine CAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage pipeline and cost reduction efforts.

Related News